Implication of RAF1 aberrations in advanced solid tumors
In conclusion, we showed that when patients with metastatic solid cancer receive NGS test, approximately 2.0% have RAF1 aberrations in their tumor specimen. Overall, our data is expected to provide valuable information to the solid tumor patients having RAF1 aberrations